by The global Adoptive Cell Therapy Market is estimated to be valued at US$ 5,992.9875 Mn in 2023 and is expected to exhibit a CAGR of 21% over the forecast period from 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Adoptive cell therapy involves engineering patients’ own immune cells to recognize and attack cancer cells. T cells extracted from a patient are genetically modified to recognize tumor antigens and expanded outside the body before being re-infused to induce an anti-tumor response. This promising treatment approach has demonstrated success in treating some types of cancers.
Market key trends:
Rising prevalence of cancer is a major driver for the adoptive cell therapy market. According to World Health Organization, cancer burden has risen to 18.1 million new cases and 9.6 million cancer deaths in 2018. Growing demand for personalized medicine and development of chimeric antigen receptor (CAR) T-cell therapies is fueling the adoption of adoptive cell therapy. In 2018, the U.S. Food and Drug Administration approved two CAR T-cell therapies Kymriah and Yescarta for treatment of cancers of blood. Positive clinical trial results and approval of more CAR T therapies for hematologic as well as solid tumors in the coming years will support the market growth over the forecast period.
Market key trends:
One of the key trends in the adoptive cell therapy market is the rise in clinical trials for new therapeutic applications. The market has witnessed a significant increase in ongoing clinical trials to evaluate cell therapies for various cancer types including leukemia, melanoma, lymphoma, and others. For instance, in 2020, Novartis announced positive results from its phase III study evaluating Kymriah in patients with relapsed or refractory follicular lymphoma. Similarly, Gilead’s phase III trial of Yescarta in second-line large B-cell lymphoma also showed positive results. The successful clinical trials are demonstrating the potential of these adoptive cell therapies in the treatment of various cancers and facilitating their approvals and commercialization. This is expected to boost the adoptive cell therapy market during the forecast period.
SWOT Analysis
Strength: Targeted approach towards eliminating only cancerous cells leads to less side effects compared to other treatment methods.
Weakness: High costs associated with development and manufacturing of personalized therapies. Complex ex-vivo production processes add to the overall costs.
Opportunity: Rising clinical success rates and regulatory approvals for new therapeutic applications in cancer and other diseases. Growing investment and partnerships between pharmaceutical companies and clinical trial developers.
Threats: Safety issues such as cytokine release syndrome can limit the adoption of these therapies. Challenges in manufacturing and complexity of operations pose threat to timely availability.
Key Takeaways
The Global Adoptive Cell Therapy Market Size was valued at US$ 5992.9875 Mn in 2023 and is expected to witness high growth, exhibiting a CAGR of 21% over the forecast period of 2023 to 2030, due to increasing prevalence of cancer worldwide.
Regional analysis: North America dominated the global adoptive cell therapy market in 2023 due to presence of major market players, higher awareness levels regarding advanced treatment methods, and rapid FDA approvals for new immune cell therapies in the region. The Asia Pacific market is expected to exhibit fastest growth between 2023 to 2030 owing to rising healthcare spending, growing incidences of cancer, and increasing focus of international players on establishing manufacturing facilities and clinical research in countries such as China and India.
Key players operating in the adoptive cell therapy market are Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs. These players are involved in various organic and inorganic growth strategies to gain a competitive advantage in the market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
